Connection

Jordan Elm to Humans

Back to Details
This is a "connection" page, showing publications Jordan Elm has written about Humans.
Jordan Elm
Connection Strength
0.545
Humans
  1. A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial. Contemp Clin Trials. 2019 11; 86:105852.
    View in: PubMed
    Score: 0.026
  2. Levetiracetam no better than phenytoin in children with convulsive status epilepticus. Lancet. 2019 05 25; 393(10186):2101-2102.
    View in: PubMed
    Score: 0.026
  3. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke. 2017 07; 48(7):2007-2012.
    View in: PubMed
    Score: 0.022
  4. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21.
    View in: PubMed
    Score: 0.016
  5. Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
    View in: PubMed
    Score: 0.015
  6. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.011
  7. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
    View in: PubMed
    Score: 0.011
  8. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.010
  9. Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled Trial. Stroke. 2023 Apr; 54(4):912-920.
    View in: PubMed
    Score: 0.008
  10. Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. Stroke. 2021 10; 52(10):e635-e645.
    View in: PubMed
    Score: 0.008
  11. Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. Int J Stroke. 2022 08; 17(7):806-809.
    View in: PubMed
    Score: 0.008
  12. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021 08 17; 97(7):e720-e727.
    View in: PubMed
    Score: 0.007
  13. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021 07; 14(4):1444-1451.
    View in: PubMed
    Score: 0.007
  14. Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus. Neurology. 2021 05 11; 96(19):e2372-e2386.
    View in: PubMed
    Score: 0.007
  15. Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. J Am Heart Assoc. 2021 03 16; 10(6):e019362.
    View in: PubMed
    Score: 0.007
  16. The Utility of Domain-Specific End Points in Acute Stroke Trials. Stroke. 2021 03; 52(3):1154-1161.
    View in: PubMed
    Score: 0.007
  17. Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia. 2021 03; 62(3):795-806.
    View in: PubMed
    Score: 0.007
  18. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. J Clin Pharmacol. 2021 06; 61(6):763-768.
    View in: PubMed
    Score: 0.007
  19. Electroencephalographic Seizures in Emergency Department Patients After Treatment for Convulsive Status Epilepticus. J Clin Neurophysiol. 2022 09 01; 39(6):441-445.
    View in: PubMed
    Score: 0.007
  20. The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods. Int J Stroke. 2021 10; 16(7):873-880.
    View in: PubMed
    Score: 0.007
  21. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
    View in: PubMed
    Score: 0.007
  22. National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond. Stroke. 2020 08; 51(8):2580-2586.
    View in: PubMed
    Score: 0.007
  23. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020 07; 51(7):2058-2065.
    View in: PubMed
    Score: 0.007
  24. Clinical Implementation of Transcranial Direct Current Stimulation in Aphasia: A Survey of Speech-Language Pathologists. Am J Speech Lang Pathol. 2020 08 04; 29(3):1376-1388.
    View in: PubMed
    Score: 0.007
  25. The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.
    View in: PubMed
    Score: 0.007
  26. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.
    View in: PubMed
    Score: 0.007
  27. Framework for advancing rigorous research. Elife. 2020 03 04; 9.
    View in: PubMed
    Score: 0.007
  28. Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 03; 51(3):792-799.
    View in: PubMed
    Score: 0.007
  29. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 12 01; 76(12):1466-1473.
    View in: PubMed
    Score: 0.007
  30. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.
    View in: PubMed
    Score: 0.007
  31. Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.
    View in: PubMed
    Score: 0.007
  32. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
    View in: PubMed
    Score: 0.007
  33. Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. Acad Emerg Med. 2019 08; 26(8):940-943.
    View in: PubMed
    Score: 0.006
  34. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
    View in: PubMed
    Score: 0.006
  35. Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation. 2019 08 20; 140(8):658-664.
    View in: PubMed
    Score: 0.006
  36. Factors Influencing Oral Intake Improvement and Feeding Tube Dependency in Patients with Poststroke Dysphagia. J Stroke Cerebrovasc Dis. 2019 Jun; 28(6):1421-1430.
    View in: PubMed
    Score: 0.006
  37. Mapping acute lesion locations to physiological swallow impairments after stroke. Neuroimage Clin. 2019; 22:101685.
    View in: PubMed
    Score: 0.006
  38. Statistical Methodology for Multiclass Classifications: Applications to Dementia. J Alzheimers Dis. 2019; 68(1):173-186.
    View in: PubMed
    Score: 0.006
  39. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease. BMC Med Inform Decis Mak. 2018 12 20; 18(1):138.
    View in: PubMed
    Score: 0.006
  40. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018 12 01; 75(12):1470-1476.
    View in: PubMed
    Score: 0.006
  41. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018 12 04; 91(23):e2163-e2169.
    View in: PubMed
    Score: 0.006
  42. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. Stroke. 2018 11; 49(11):2652-2658.
    View in: PubMed
    Score: 0.006
  43. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018 Nov - Dec; 11(6):1276-1281.
    View in: PubMed
    Score: 0.006
  44. Long-Term Outcomes in Patients Aged =70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018 06; 49(6):1457-1463.
    View in: PubMed
    Score: 0.006
  45. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
    View in: PubMed
    Score: 0.006
  46. Differences in swallow physiology in patients with left and right hemispheric strokes. Physiol Behav. 2018 10 01; 194:144-152.
    View in: PubMed
    Score: 0.006
  47. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017 Nov; 82(5):755-765.
    View in: PubMed
    Score: 0.006
  48. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143.
    View in: PubMed
    Score: 0.006
  49. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
    View in: PubMed
    Score: 0.005
  50. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 12; 33:127-133.
    View in: PubMed
    Score: 0.005
  51. Communicating with participants during the conduct of multi-center clinical trials. Clin Trials. 2016 12; 13(6):592-596.
    View in: PubMed
    Score: 0.005
  52. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct; 15(11):1160-9.
    View in: PubMed
    Score: 0.005
  53. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.
    View in: PubMed
    Score: 0.005
  54. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocrit Care. 2016 Feb; 24(1):132-9.
    View in: PubMed
    Score: 0.005
  55. Human Data Supporting Glyburide in Ischemic Stroke. Acta Neurochir Suppl. 2016; 121:13-8.
    View in: PubMed
    Score: 0.005
  56. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002.
    View in: PubMed
    Score: 0.005
  57. Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. Stroke. 2015 Aug; 46(8):2238-43.
    View in: PubMed
    Score: 0.005
  58. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
    View in: PubMed
    Score: 0.005
  59. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. J Parkinsons Dis. 2015; 5(1):67-73.
    View in: PubMed
    Score: 0.005
  60. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis. 2015; 5(4):731-6.
    View in: PubMed
    Score: 0.005
  61. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
    View in: PubMed
    Score: 0.005
  62. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug; 21(1):43-51.
    View in: PubMed
    Score: 0.005
  63. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr; 20(2):193-201.
    View in: PubMed
    Score: 0.005
  64. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb; 29(2):263-5.
    View in: PubMed
    Score: 0.004
  65. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan; 45(1):281-3.
    View in: PubMed
    Score: 0.004
  66. The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92.
    View in: PubMed
    Score: 0.004
  67. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug; 66(8 Suppl):S130-7.
    View in: PubMed
    Score: 0.004
  68. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
    View in: PubMed
    Score: 0.004
  69. Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Stat Methods Med Res. 2016 04; 25(2):821-37.
    View in: PubMed
    Score: 0.004
  70. Fall frequency and risk assessment in early Parkinson's disease. Parkinsonism Relat Disord. 2012 Aug; 18(7):837-41.
    View in: PubMed
    Score: 0.004
  71. A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials. 2012 Apr; 9(2):188-97.
    View in: PubMed
    Score: 0.004
  72. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7.
    View in: PubMed
    Score: 0.004
  73. Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013 Aug; 22(6):742-9.
    View in: PubMed
    Score: 0.004
  74. How common is brain atrophy in patients with medial temporal lobe epilepsy? Epilepsia. 2010 Sep; 51(9):1774-9.
    View in: PubMed
    Score: 0.004
  75. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12.
    View in: PubMed
    Score: 0.003
  76. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.003
  77. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.003
  78. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
    View in: PubMed
    Score: 0.003
  79. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
    View in: PubMed
    Score: 0.003
  80. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.